


Vebicorvir

Chemical Properties

CAS No. : 2090064-66-5
 Formula: C₁₉H₁₂F₃N₃O₄S₂
 Molecular Weight: 467.44
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.



Biological Description

Description	Vebicorvir (ABI-H0731), a first-generation hepatitis B virus (HBV) core protein inhibitor, has demonstrated effective antiviral activity.
Targets(IC50)	HBV
In vitro	Vebicorvir exhibited selective inhibition of HBV DNA replication (50% effective concentration [EC ₅₀] from 173 nM to 307 nM). Most importantly, Vebicorvir suppressed covalently closed circular DNA (cccDNA) formation in two de novo infection models with EC ₅₀ s from 1.84 μM to 7.3 μM. Mechanism-of-action studies indicated that Vebicorvir is a direct-acting antiviral that targets HBV core protein, preventing HBV pregenomic RNA (pgRNA) encapsidation and subsequent DNA replication.

Solubility Information

Solubility	DMSO: 60 mg/mL (128.36 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Corn Oil: 2.5 mg/mL (5.35 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1393 mL	10.6966 mL	21.3931 mL
5 mM	0.4279 mL	2.1393 mL	4.2786 mL
10 mM	0.2139 mL	1.0697 mL	2.1393 mL
50 mM	0.0428 mL	0.2139 mL	0.4279 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Huang Q, Cai D, Yan R, Li L, Zong Y, Guo L, Mercier A, Zhou Y, Tang A, Henne K, Colonno R. Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731. *Antimicrob Agents Chemother.* 2020 Oct 20;64(11):e01463-20.

Smolders EJ, Burger DM, Feld JJ, Kiser JJ. Review article: clinical pharmacology of current and investigational hepatitis B virus therapies. *Aliment Pharmacol Ther.* 2020 Jan;51(2):231-243. doi: 10.1111/apt.15581. Epub 2019 Dec 16.

Yuen MF, Agarwal K, Gane EJ, Schwabe C, Ahn SH, Kim DJ, Lim YS, Cheng W, Sievert W, Visvanathan K, Ruby E, Liaw S, Yan R, Huang Q, Colonno R, Lopatin U. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. *Lancet Gastroenterol Hepatol.* 2020 Feb;5(2):152-166.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481